Navigation

Ovarian cancer (relapsed) - trabectedin

Trabectedin for the treatment of relapsed ovarian cancer

Status: History
Expected date of issue: TBC
Referral date: November 2008
Process: STA
Notes:

Since issuing the FAD, the manufacturer have requested to make a submission including a patient access scheme. This scheme has been approved by the Department of Health and in recognition of the exceptional circumstances, NICE has agreed that the appraisal can be referred back to the Appraisal Committee. The appeal stage of this appraisal topic has been suspended. This will allow for the Appraisal Committee to consider the new evidence submitted.

Topic area:
  • Cancer
  • Gynaecology, pregnancy and birth
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Sally Doss
Communications manager: Laura Gibson
Project manager: Bijal Joshi
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 04 February 2010
1st appraisal committee meeting: 18 May 2010
2nd appraisal committee meeting 22 July 2010
3rd appraisal committee meeting: 18 January 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • PharmaMar (trabectedin)

Patient/carer groups

  • Afiya Trust
  • Black Health Agency
  • CANCERactive
  • Cancer Black Care
  • Cancer Equality
  • Chinese National Healthy Living Centre
  • Confederation of Indian Organisations
  • Counsel and Care
  • Equalities National Council
  • Gynae C
  • Helen Rollason Heal Cancer Charity
  • Macmillan Cancer Support
  • Maggie’s Centres
  • Marie Curie Cancer Care
  • Muslim Council of Great Britain
  • Muslim Health Network
  • National Cancer Alliance
  • National Council for Palliative Care
  • Ovacome
  • Ovarian Cancer Action
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • Sue Ryder Care
  • Target Ovarian Cancer
  • Tenovus
  • Well Being of Women
  • Women’s Health Concern

Professional groups

  • Association of Cancer Physicians
  • British Association for Services to the Elderly
  • British Geriatrics Society
  • British Gynaecological Cancer Society
  • British Oncological Association (BOA)
  • British Psychosocial Oncology Society
  • Cancer Networks Pharmacists Forum
  • Cancer Research UK
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Obstetricians & Gynaecologists
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • Royal Pharmaceutical Society
  • Royal Society of Medicine – Intellectual Disabilities Forum
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom Oncology Nursing Society

Others

  • Blackpool PCT
  • Carmarthenshire LHB
  • Department of Health
  • Welsh Assembly Government

General

  • Board of Community Health Councils in Wales
  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • National Public Health Service for Wales
  • NHS Alliance
  • NHS Confederation
  • NHS Purchasing and Supply Agency
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • Accord Healthcare (gemcitabine)
  • Actavis UK (gemcitabine, paclitaxel)
  • Bristol-Myers Squibb (paclitaxel)
  • Eli Lilly (gemcitabine)
  • GlaxoSmithKline (topotecan)
  • Hospira UK (carboplatin, cisplatin gemcitabine, paclitaxel)
  • Mayne Pharma (paclitaxel)
  • Medac GmbH (gemcitabine, paclitaxel)
  • Pfizer (cisplatin)
  • Schering-plough (pegylated liposomal doxorubicin hydrochloride)
  • Stragen UK (paclitaxel)
  • Sun Pharmaceuticals UK (gemcitabine)
  • Teva UK (gemcitabine, paclitaxel)
  • Wockhardt UK (paclitaxel)

Relevant research groups

  • Eve appeal
  • Institute of Cancer Research
  • MRC Clinical Trials Unit
  • National Cancer Research Institute
  • National Cancer Research Network
  • National Institute for Health Research
  • Policy Research Institute on Ageing and Ethnicity
  • Research Institute for the Care of Older People

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Key documents

This page was last updated: 04 May 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.